Effect of conversion to enteric-coated mycophenolate sodium on gastrointestine-related quality of life after renal transplantation
10.3760/cma.j.issn.0254-1785.2014.08.008
- VernacularTitle:肾移植术后转换应用麦考酚钠肠溶片对胃肠道相关生活质量的影响
- Author:
Xuping YAO
;
Shuwei ZHANG
;
Wenbo GAO
;
Guobin WENG
- Publication Type:Journal Article
- Keywords:
Kidney transplantation;
Mycophenolate mofetil;
Gastrointestinal symptoms;
Enteric-coated mycophenolate sodium
- From:
Chinese Journal of Organ Transplantation
2014;35(8):479-482
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the effect of conversion from mycophenolat mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPS) on gastrointestine-related quality of life,as well as the safety and efficacy.Method A total of 41 renal transplant (RT) recipients were converted from MMF to EC-MPS (46.3 ± 17.1) months after the operation due to the gastrointestinal side effects of MMF,with a mean time of 46.3 months.Before the conversion and 12 weeks later,the patients were evaluated with Gastrointestinal Quality of Life Index (GIQLI) questionnaire,and the safety and efficacy were assessed.Result The average dose of MMF was 846.7 ± 291.3 mg/day before the conversion,with a mean dose of 639.5 ± 186.4 mg/day for EC-MPS.The total score of GIQLI was 103.6 ± 10.7 before the conversion,and 12 weeks after conversion 118.3 ± 15.1,with a statistical significance (P＜0.05).The safety of EC-MPS was excellent without infection,acute rejection episode,loss of allograft or death.The serum creatine was 136.9 ± 35.7 mol/L before conversion and 128.4± 40.8 mol/L after conversion (P ＞ 0.05).Conclusion For the RT patients with gastrointestinal side effects of MMF,conversion to EC-MPS could significantly alleviate gastrointestinal illness,and improve quality of life,with excellent safety and efficacy.
